FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins and mRNA for the biotech industry, announced today the addition of three reporter Self-amplifying RNA (saRNA) products to its growing catalog: AldGFP saRNA™, AldSEAP saRNA™ and AldnLUC saRNA™.
Alphavirus-derived saRNA encodes nonstructural proteins that enable self-replication, thereby allowing lower doses for genetic medicines and vaccines, and saRNA is being used to support next-generation COVID vaccine development. For these uses, Aldevron’s novel saRNA reporters enable rapid technology evaluation and delivery optimization.
“The use of saRNA to fight disease is growing exponentially and we are committed to providing our clients the highest quality biologics to support their work,” says Nate Spangler, Director of Innovation and Strategy for Aldevron. “We stock these reporter saRNAs for immediate delivery, and we can custom manufacture saRNA encoding any gene of interest."
The AldGFP saRNA™, AldSEAP saRNA™ and AldnLUC saRNA™ constructs are offered royalty free for research use only and are available in packs of 200 µg, 1mg and custom sizes.
Aldevron is a privately held company founded in 1998. It serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components for vaccine development, gene and cell therapy, immunotherapy, agricultural biotech, veterinary medicines, molecular diagnostics and more. Aldevron is known for inventing the GMP-Source® quality system, and for specializing in GMP manufacturing, operating the world’s largest facility at its Company headquarters in Fargo, North Dakota. The company’s protein development and manufacturing operations are located in Madison, Wisconsin. To learn more, visit www.aldevron.com.